Seres Therapeutics (MCRB) Stock Price, News & Analysis

Company Overview

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection. Seres is also advancing SER-287 in ulcerative colitis, SER-401 in combination with immunotherapy for certain cancers, and other preclinical programs targeting metabolic and inflammatory diseases. The company collaborates with strategic partners, including Nestlé Health Science, to support development, manufacturing scale-up and global research efforts.

Founded in 2010, Seres went public in 2015 to further accelerate its clinical pipeline. The management team comprises experienced biotech executives, clinicians and scientists with expertise in microbiome research and product development. Seres continues to conduct multi‐center clinical trials across North America and Europe, seeking to bring first‐in‐class microbiome therapies to patients with limited treatment options.

Key Stats

• Today's Range: $19.14 to $22.00
• 50-Day Range: $12.15 to $22.85
• 52-Week Range: $6.53 to $24.67
• Volume: 264,845 shs
• Average Volume: 268,113 shs
• Market Capitalization: $180.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.33
• Consensus Rating: Reduce

Seres Therapeutics Stock Analysis - MarketRank™

Seres Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 592nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Seres Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on 1 buy rating, 1 hold rating, and 3 sell ratings.

Downside Risk

Seres Therapeutics has a consensus price target of $14.33, representing about 30.4% downside from its current price of $20.59.

Amount of Analyst Coverage

Seres Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Seres Therapeutics are expected to decrease in the coming year, from ($0.38) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Seres Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Seres Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Seres Therapeutics has a P/B Ratio of 12.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.47% of the float of Seres Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Seres Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Seres Therapeutics has recently decreased by 7.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Seres Therapeutics does not currently pay a dividend.

Dividend Growth

Seres Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.14

Percentage of Shares Shorted

14.47% of the float of Seres Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Seres Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Seres Therapeutics has recently decreased by 7.30%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.55

News Sentiment

Seres Therapeutics has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.

Search Interest

24 people have searched for MCRB on MarketBeat in the last 30 days. This is an increase of 243% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Seres Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of Seres Therapeutics is held by insiders.

Percentage Held by Institutions

59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MCRB Stock Analysis - Frequently Asked Questions

How have MCRB shares performed this year?

Seres Therapeutics' stock was trading at $16.62 at the beginning of 2025. Since then, MCRB stock has increased by 23.9% and is now trading at $20.59.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) released its earnings results on Wednesday, August, 6th. The biotechnology company reported ($2.27) EPS for the quarter, beating the consensus estimate of ($2.72) by $0.45.
Read the conference call transcript.

When did Seres Therapeutics' stock split?

Shares of Seres Therapeutics reverse split before market open on Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Seres Therapeutics IPO?

Seres Therapeutics (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include PayPal (PYPL), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Micron Technology (MU), QUALCOMM (QCOM) and NIO (NIO).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 10/04/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MCRB
• CIK: 1609809
• Web: www.serestherapeutics.com
• Phone: (617) 945-9626
• Fax: N/A
• Employees: 330
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Seres Therapeutics: $14.33
• High Price Target: $22.00
• Low Price Target: $6.00
• Potential Upside/Downside: -30.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $140 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -350.16%
• Return on Assets: -67.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.57
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $126.32 million
• Price / Sales: 1.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 12.79

Miscellaneous

• Outstanding Shares: 8,750,000
• Free Float: 8,344,000
• Market Cap: $180.16 million
• Optionable: Optionable
• Beta: 0.19